Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
Recruiting · NCT06145841 · Observational (researchers observe without assigning treatment) · Lead sponsor: Guangzhou 8th People's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Pathogen metagenomic next-generation sequencing
What this trial is about
This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and/or sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Confirmed HIV infection;
- Progression to AIDS stage: CD4+ count \<200 cells/ul and/or occurrence of AIDS opportunistic infections;
- Age between 18 and 65 years;
- Meeting the diagnosis of severe pneumonia or septic shock:
- The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;
- The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's "Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2018).
Exclusion criteria
- Coexisting central nervous system lesions, severe liver disease, or cirrhosis;
- Concurrent AIDS-related or unrelated tumors;
- Women who are pregnant or breastfeeding;
- Severe underlying diseases of the heart, lungs, liver, kidneys, etc.;
- Alcohol abuse or drug use;
- The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial.
Where it is running
1 location listed.
- Linghua Li - Guangzhou, Guangdong, China